antibody

Rabbit anti Human SNCA  Monoclonal Antibody

MBS2544336

0.06 mL

215 USD

monoclonal

rabbit

nonconjugated

western blot, ELISA, immunoprecipitation, enzyme immunoassay

Antibody

Rabbit anti Human SNCA  Monoclonal Antibody

[SNCA ]

[SNCA, partial; Alpha-synuclein; alpha-synuclein; synuclein alpha; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP]

[SNCA ]

[SNCA; SNCA; PD1; NACP; PARK1; PARK4; NACP; PARK1; NACP]

SYUA_HUMAN

Monoclonal

IgG

Rabbit

Human

140

Store at -20 degree C. Avoid freeze / thaw cycles

Western Blot (WB), ELISA (EIA), Immunoprecipitation (IP)

WB: 1/100-1/200. ELISA: 1/5000-1/10000. IP: 1/250-1/500

Western Blot

IP

Immunogen: Recombinant Human SNCA / alpha-Synuclein protein

Buffer: PBS with 0.05% sodium azide, 30% glycerol and 5% trehalose. Produce: This antibody was obtained from a rabbit immunized with purified, recombinant Human SNCA / alpha-Synuclein.

Alpha-Synuclein (alpha-Syn), also known as NACP or SNCA, exists as at least two structural isoforms: one is helix-rich, membrane-bound form that both the N- and C-terminal regions of alpha-synuclein are tightly associated with membranes and the other is disordered, cytosolic form. Synuclein is found predominantly in the presynaptic termini, in both free or membrane-bound forms. SNCA is extensively localized in nucleus of neurons. It has been shown that alpha-Synuclein was highly expressed in the mitochondria in olfactory bulb, hippocampus, striatum, and thalamus, where the cytosolic alpha-Synuclein was also rich. Normally the unstructured soluble type of alpha-synuclein can aggregate to form insoluble fibrils in pathological conditions characterized by Lewy bodies, such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. SNCA abnormality and mitochondrial deficiency are two major changes in the brain of patients with Parkinson's disease (PD). In addition, alpha-synuclein is an abundant component of Lewy bodies in sporadic Parkinson's disease and diffuse Lewy body disease.

49456267

Alpha-synuclein Signaling Pathway (137913); Alzheimer's Disease Pathway (83097); Alzheimer's Disease Pathway (509); Alzheimers Disease Pathway (672448); Amyloid Fiber Formation Pathway (1269169); Ectoderm Differentiation Pathway (1458276); Metabolism Of Proteins Pathway (1268677); Parkin-Ubiquitin Proteasomal System Pathway (700638); Parkinson's Disease Pathway (83098); Parkinsons Disease Pathway (705377)

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Alternatively spliced transcripts encoding different isoforms have been identified for this gene. [provided by RefSeq, Feb 2016]

SNCA: a member of the synuclein family. Abundantly expressed in the brain. Inhibits phospholipase D2 selectively. May integrate presynaptic signaling and membrane trafficking. Implicated in the pathogenesis of Parkinson's disease. A major component of amyloid plaques in the brains of patients with Alzheimer's disease. Two alternatively spliced isoforms transcripts have been identified. Protein type: Adaptor/scaffold. Chromosomal Location of Human Ortholog: 4q21. Cellular Component: actin cytoskeleton; axon; cell cortex; cytoplasm; cytosol; extracellular region; extracellular space; fibril; growth cone; inclusion body; lysosome; membrane; mitochondrial respiratory chain complex I; mitochondrion; nucleus; perinuclear region of cytoplasm; plasma membrane; platelet alpha granule membrane. Molecular Function: alpha-tubulin binding; calcium ion binding; caspase inhibitor activity; copper ion binding; dynein binding; fatty acid binding; ferrous iron binding; histone binding; identical protein binding; kinesin binding; magnesium ion binding; oxidoreductase activity; phospholipid binding; phosphoprotein binding; protein binding; tau protein binding; zinc ion binding. Biological Process: calcium ion homeostasis; caspase activation; cellular protein metabolic process; dopamine biosynthetic process; dopamine uptake; fibril organization and biogenesis; microglial cell activation; negative regulation of apoptosis; negative regulation of caspase activity; negative regulation of dopamine uptake; negative regulation of exocytosis; negative regulation of histone acetylation; negative regulation of microtubule polymerization; negative regulation of monooxygenase activity; negative regulation of norepinephrine uptake; negative regulation of serotonin uptake; negative regulation of transcription from RNA polymerase II promoter; negative regulation of transporter activity; positive regulation of apoptosis; positive regulation of endocytosis; positive regulation of peptidyl-serine phosphorylation; positive regulation of receptor recycling; positive regulation of release of sequestered calcium ion into cytosol; protein destabilization; receptor internalization; regulation of dopamine secretion; response to iron(II) ion; response to lipopolysaccharide; response to magnesium ion; synaptic vesicle endocytosis. Disease: Dementia, Lewy Body; Parkinson Disease 1, Autosomal Dominant; Parkinson Disease 4, Autosomal Dominant

0.06 mL

215 USD

0.12 mL

330

0.2 mL

500